TikoMed AB and IQVIA announce a key strategic collaboration with the aim to accelerate the development of TikoMed's lead drug platform candidate ILB®, a broad-spectrum small molecule drug candidate with curative potential in a wide range of diseases driven by acute and chronic inflammation. The collaboration will support TikoMed's clinical development, regulatory and commercial strategies. IQVIA brings together deep therapeutic expertise, unparalleled data, and technology alongside flexible operating models to enable biopharma organisation's such as TikoMed to accelerate the clinical development and commercialisation of innovative products that improve patient lives.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
223.4 USD | +0.55% | -4.90% | -3.46% |
03/05 | UBS Adjusts Price Target on IQVIA Holdings to $295 From $300, Maintains Buy Rating | MT |
03/05 | Deutsche Bank Adjusts Price Target on IQVIA Holdings to $275 From $280 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.46% | 40.43B | |
+25.69% | 48.09B | |
+46.90% | 40.62B | |
-6.20% | 28.36B | |
+9.17% | 24.89B | |
-20.42% | 19.01B | |
+28.07% | 12.09B | |
+0.17% | 11.88B | |
-1.24% | 11.8B | |
+19.33% | 11.45B |
- Stock Market
- Equities
- IQV Stock
- News Iqvia Holdings Inc.
- TikoMed AB and IQVIA Announce Strategic Collaboration for the Development of TikoMed's Lead Drug Platform Candidate ILB®